Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
7.99
-0.24 (-2.92%)
Apr 17, 2025, 4:00 PM EDT - Market closed

Actuate Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Actuate Therapeutics stock has a target of 20, which predicts an increase of 150.31% from the current stock price of 7.99.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $20 $20 $20 $20
Change +150.31% +150.31% +150.31% +150.31%
* Price targets were last updated on Mar 17, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for Actuate Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Mar '25Apr '25
Strong Buy 11
Buy 00
Hold 00
Sell 00
Strong Sell 00
Total 11

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Initiates
$20
Strong Buy Initiates $20 +150.31% Mar 17, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.15
from -3.26
EPS Next Year
-1.41
from -1.15
Fiscal Year FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
---
Revenue Growth
------
EPS
-16.65-17.24-3.26-1.15-1.41-1.64
EPS Growth
------
Forward PE
------
No. Analysts ---444
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 202520262027
High n/a n/a n/a
Avg n/a n/a n/a
Low n/a n/a n/a

Revenue Growth

Revenue Growth 202520262027
High - - -
Avg - - -
Low - - -

EPS Forecast

EPS 202520262027
High -0.83 -1.03 -1.11
Avg -1.15 -1.41 -1.64
Low -1.43 -1.74 -2.12

EPS Growth

EPS Growth 202520262027
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.